News & Views - Telix Pharmaceuticals Limited | Telix Pharmaceuticals Limited

Telix Joins Thera4Care with TLX400-Tx to Accelerate Translation of Next Generation FAP-Targeting Theranostics

Telix today announces that it has joined Thera4Care, an initiative aimed at establishing an integrated, collaborative ecosystem for theranostics (therapeutic and diagnostic radiopharmaceuticals) to broaden patient access in Europe. The project includes 27 partners from top European academic centers, healthcare providers, industry stakeholders, and patient advocacy groups.

Telix Notice of General Meeting

Telix today announces a General Meeting of shareholders to be held at The Events Centre, Level 5, Tower 2/727 Collins Street, Melbourne, VIC 3008 and online via meetings.openbriefing.com/TLXMeeting2026 on Tuesday, December 1, 2026 at 10:00 a.m. (Melbourne time).

Telix reports Third Quarter 2026 Financial Performance

Telix provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026).

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Telix and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, today announced a collaboration to advance scalable United States (U.S.) production of astatine-211 (211At), an alpha-emitting radioisotope being investigated for targeted alpha therapy.

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

Telix today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna, Austria from October 17-21, 2026.

Telix to Host Capital Markets Day in Melbourne on November 4, 2026

Telix today advises that it will host advises that it will host a Capital Markets Day in Melbourne, Australia, on Wednesday, November 4, 2026, from 9:00 a.m. to 12:30 p.m. (AEDT).

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

Telix today announces that the first patients in the United States (U.S.) have been dosed with Pixclara® (floretyrosine F 18 or 18F-FET), its FDA-approved, amino acid positron emission tomography (PET) drug for glioma (brain cancer) imaging.

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging

Telix today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s BiPASS® program, evaluating gallium-68 (68Ga) PSMA-PET imaging in combination with MRI for the detection of prostate cancer prior to biopsy.

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

Telix today announces it has signed a strategic agreement to combine with ITM Isotope Technologies Munich SE (“ITM”), a global leader in radioisotope production and radiopharmaceutical development.

FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).